Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07489651
PHASE2

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Sponsor: Reunion Neuroscience Inc

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Official title: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder

Key Details

Gender

All

Age Range

18 Years - 74 Years

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2026-04

Completion Date

2027-04

Last Updated

2026-03-24

Healthy Volunteers

No

Interventions

DRUG

RE104 for Injection

Single, subcutaneous dose of RE104 for Injection

DRUG

Placebo

Single, subcutaneous dose of 0.9% sodium chloride for injection